Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

649
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
649
Analgesia and Pain Management01:25

Analgesia and Pain Management

1.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

875
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
875

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Academic Integrity and Cheating in Dental Education: Prevalence, Drivers, and Career Implications.

Dentistry journal·2026
Same author

Cannabinoid Signaling and Autophagy in Oral Disease: Molecular Mechanisms and Therapeutic Implications.

International journal of molecular sciences·2026
Same author

The Role of Short-Chain Fatty Acids (SCFAs) in Colic and Anti-Inflammatory Pathways in Horses.

Animals : an open access journal from MDPI·2025
Same author

Exploring the Role of Oral Microbiota in the Pathophysiology and Treatment of Bruxism.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

<i>Akkermansia muciniphila</i> as a Potential Guardian against Oral Health Diseases: A Narrative Review.

Nutrients·2024
Same author

The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr<sup>-/-</sup> Mice with Obesity.

Antioxidants (Basel, Switzerland)·2023

Related Experiment Video

Updated: Jan 7, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

327

Oral Cannabidiol for Acute Post-Extraction Pain: A Randomized Pilot Study.

Ammaar H Abidi1, Modar Kassan1, Karen Derefinko2

  • 1College of Dental Medicine, Lincoln Memorial University, Knoxville, TN 37917, USA.

Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
PubMed
Summary

This pilot study suggests higher concentrations of cannabidiol (CBD) may effectively manage dental extraction pain, comparable to standard treatments. Further research is needed to confirm these findings on pain relief.

Keywords:
acute postoperative painanalgesiacannabidiol (CBD)dental painnon-opioid therapypain managementphytocannabinoidspilot clinical trialtooth extraction

More Related Videos

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.8K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.8K

Related Experiment Videos

Last Updated: Jan 7, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

327
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.8K
Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.8K

Area of Science:

  • Oral surgery and pain management
  • Pharmacology of cannabinoids

Background:

  • Postoperative pain is a common concern after dental extractions.
  • Cannabidiol (CBD), a non-intoxicating cannabinoid, shows potential analgesic and anti-inflammatory properties.
  • CBD is being explored as an adjunct therapy for acute dental pain.

Purpose of the Study:

  • To evaluate the preliminary efficacy and safety of oral CBD for pain management after simple dental extractions.
  • To compare two CBD concentrations (17 mg/mL and 37 mg/mL) against placebo and standard non-opioid therapy (ibuprofen/acetaminophen).

Main Methods:

  • A pilot randomized trial (SWAP trial) with 8 adults in four arms (n=2 per arm): CBD 17 mg/mL, CBD 37 mg/mL, placebo, or treatment-as-usual (TAU).
  • Participants received study medication as needed for 7 days.
  • Primary endpoint: pain intensity measured by ecological momentary assessment (EMA) over 72 hours.

Main Results:

  • All participants completed follow-up with high EMA adherence (>75%).
  • Due to the small sample size, results are descriptive and preliminary.
  • The 37 mg/mL CBD group showed pain ratings comparable to the TAU group, while the 17 mg/mL CBD and placebo groups showed limited efficacy.

Conclusions:

  • Higher concentration CBD (37 mg/mL) may offer analgesia comparable to standard non-opioid therapy for post-extraction pain.
  • Findings are exploratory and suggest a potential role for higher-concentration CBD in pain management.
  • A larger, powered randomized trial is warranted to confirm these preliminary findings.